A：The new guidance range midpoint of 5 dollars 48 cents reflects a 20 cents dilution related to the X.C. Sciences acquisition.

A：The forecasted range for adjusted earnings per share for the second quarter is 1 dollar 25 cents to 1 dollar 31 cents.

A：The conservative approach in the updated guidance for the first quarter was due to a weaker respiratory season compared to historical data and the impact on other healthcare businesses like OTC Medicines.

A：The company plans to address the potential effects of an atypical respiratory season by not forecasting a make-up in Q4 for the respiratory aspect and instead focusing on the sustained growth of their medtech and pharma businesses, which have reliably performed in the past.

A：The key drivers of the company's sales forecast, excluding the impact of an unusual flu season, include the continued growth of the medtech business (low double digits), the pharma business (above 7%), the positive impact of the integration of Exact Sciences, and the trajectory of the business in China and the US.

A：The speaker suggests that the acquisition initially seemed to cause deceleration in the organic growth of the Abbott business before the addition of exact sciences, as evidenced by the shift from a growth rate of 'hoddish to a half' to 'circuit a half' guide. However, they clarify their perspective by emphasizing that if the acquisition had closed in Q2, they would have maintained separate reporting and then reconciled the organic growth rates every quarter to give investors visibility into the new addition of exact sciences.

A：The speaker believes that putting exact sciences into a comparable basis allows one to identify any underperforming parts of the non-exact sciences business. They indicate that they expect to reconcile between the acquisition's impact and the organic growth rate each quarter to maintain transparency for investors regarding the new addition.

A：The company remains very positive about the growth rates of the device and pharma portfolios, asserting that these growth rates are still strong and they expect to sustain them. They acknowledge the focus on the diagnostics and core nutrition businesses, which have known issues and areas of work, but express confidence in executing their strategy.

A：The company has a diversified strategy with various business segments, and they focus on each segment individually while also considering the company as a whole. They highlight their ability to break down the company within sectors to show performance, and although not every segment will meet expectations, they believe in the collection of attractive businesses within the company.

A：The company is bullish on the future of the CGM market, seeing it as a strong market with significant potential. They estimate that between 70 to 80 million people should be on CGM therapy, while the current market is around 10 to 12 million. They acknowledge concerns about market saturation but remain optimistic, projecting revenue growth over 15 years. They recognize periods of modest growth followed by strong acceleration and point to upcoming catalysts such as reimbursement and new product launches as factors that could drive growth.

A：The anticipated impact of upcoming catalysts includes the expected addition of close to one million people to the commercial coverage due to new reimbursement language for type 2 non-insulin coverage. This is not included in the guidance but is seen as a positive influence. Additionally, the speaker anticipates a strong market acceleration due to various catalysts, such as proposed language for reimbursement and new product introductions, which are anticipated to significantly contribute to growth.

A：To sustain strong growth in the cologuard market, strategies include integrating the business well, appointing a new leader in the business who previously led the screening business, focusing on opportunities beyond a single product in the colorectal cancer screening space, and entering therapy selection and MRD (Molecular Residual Disease) testing areas. The company aims to address the entire cancer diagnostic spectrum with coloGuard as a key growth driver.

A：International expansion with cologuard is seen as a significant opportunity due to its high growth potential and the existing strong relationships with healthcare systems and distributors in various markets. Lowering of the screening guidelines age in 2021 to 45 from 50 is expected to add new patients, and the demand for screening is anticipated to increase further, driven by factors like increased prevalence and existing capacity bottlenecks. The company aims to leverage these factors to enter new markets and grow internationally.

A：Unique aspects of the cologuard business contributing to sustainable growth include a strong sales force, a robust healthcare professional prescribing network, an integrated system that is seamless for the patient experience, and the rescreening business which is a growing segment of the customer base. These factors, along with care gap programs that help in meeting quality metrics, differentiate the business in the market and provide a solid foundation for continued growth.

A：The company decided to move the left atrial appendage closure device from the structural heart business to the electrophysiology business because they believed it would be more beneficial for the electrophysiology business, despite it being more beneficial for the structural heart business.

A：The reorganization of the company's business segments has led to a reconciliation of the impact of moving sales from the structural heart into the electrophysiology business. This reorganization has been a big contributor to the disconnect between the sales model and the delivered results.

A：The company anticipates that the structural heart business will experience high single-digit growth for the full year.

A：The new next-generation product is very exciting for the company, and moving it over to the electrophysiology business is expected to provide better acceleration for the product. This transition allows the structural heart team to focus more on vulgar products and sewing, keeping them more focused.

A：The company is seeing the impact of a comprehensive price reset at a geographic level across its nutrition business, which has led to volume growth in the U.S. adult nutrition business. They are using 2025 as a baseline and tracking the progress on a monthly basis. The company is also expanding distribution, and while early signs are encouraging, there is still work to be done regarding the portfolio.

A：The company is constantly evaluating its portfolio for value creation, assessing whether the market is still attractive and examining its competitive position. This evaluation happens on an ongoing basis with management and with the board at least once a year, sometimes twice. The company seeks to make disciplined long-term strategic decisions rather than focusing solely on the short term.

A：Abbott has built its infrastructure to withstand such events, monitors and manages costs closely, and has a team in place to negotiate with suppliers and enhance efficiency. They focus on keeping a minimal backorder impact by ensuring product availability in regions with warehouses.

A：The conflict's impact on Abbott's demand has been minimal and is more about getting product into the region due to shipping challenges and demand for various supply and transport methods. Abbott has managed to keep inventory levels efficient, avoiding backorders, but has focused on increasing inventory in affiliates and warehouses in affected areas to ensure product availability.

A：The EP franchise and the Volt launch are significant for Abbott, with the US set to follow the European launch. Both products are in a limited market release phase, which is part of Abbott's controlled process to understand resourcing and positioning better before a full launch. The feedback on these products has been extremely favorable, with the introduction of features like conscious sedation in Volt. The company is optimistic about market growth, aiming to outperform the market with a focus on both efficiency and improved patient outcomes.

A：In the core lab business, China experienced flat sales in Q1 compared to the previous year due to some price and volume headwinds, leading to an estimated single-digit decline for the year. In contrast, the U.S. experienced growth in the high single digits with successful contract renewals. Europe's growth varied, with different situations in the north and south, but generally had single-digit growth. Overall, Abbott expects mid-single-digit growth for its core lab business in Europe for the year.